CD274 and prostate cancer: Prostate cancer’s low presence of tumor-infiltrating lymphocytes (TILs) contributes to immunotherapies targeting immune checkpoints, such as anti-PD-1 or anti-PD-L1 antibodies (Sharma and Allison, 2015; Gao et al., 2017; Subudhi et al., 2020).